GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » E10

United Therapeutics (United Therapeutics) E10 : $12.96 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

United Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $4.360. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $12.96 for the trailing ten years ended in Dec. 2023.

During the past 12 months, United Therapeutics's average E10 Growth Rate was 17.50% per year. During the past 3 years, the average E10 Growth Rate was 15.30% per year. During the past 5 years, the average E10 Growth Rate was 12.30% per year. During the past 10 years, the average E10 Growth Rate was 20.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of United Therapeutics was 85.90% per year. The lowest was 8.60% per year. And the median was 28.70% per year.

As of today (2024-04-27), United Therapeutics's current stock price is $233.85. United Therapeutics's E10 for the quarter that ended in Dec. 2023 was $12.96. United Therapeutics's Shiller PE Ratio of today is 18.04.

During the past 13 years, the highest Shiller PE Ratio of United Therapeutics was 80.06. The lowest was 10.81. And the median was 21.68.


United Therapeutics E10 Historical Data

The historical data trend for United Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics E10 Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.40 8.45 9.62 11.03 12.96

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.03 11.54 12.00 12.48 12.96

Competitive Comparison of United Therapeutics's E10

For the Biotechnology subindustry, United Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Shiller PE Ratio falls into.



United Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.36/129.4194*129.4194
=4.360

Current CPI (Dec. 2023) = 129.4194.

United Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 2.430 99.695 3.155
201406 2.100 100.560 2.703
201409 -0.530 100.428 -0.683
201412 2.170 99.070 2.835
201503 -0.360 99.621 -0.468
201506 1.910 100.684 2.455
201509 9.240 100.392 11.912
201512 2.100 99.792 2.723
201603 4.840 100.470 6.235
201606 4.390 101.688 5.587
201609 3.500 101.861 4.447
201612 2.430 101.863 3.087
201703 3.890 102.862 4.894
201706 -1.250 103.349 -1.565
201709 6.270 104.136 7.792
201712 0.430 104.011 0.535
201803 5.570 105.290 6.847
201806 3.980 106.317 4.845
201809 2.420 106.507 2.941
201812 1.480 105.998 1.807
201903 -11.320 107.251 -13.660
201906 4.660 108.070 5.581
201909 3.010 108.329 3.596
201912 1.200 108.420 1.432
202003 3.120 108.902 3.708
202006 2.410 108.767 2.868
202009 3.840 109.815 4.526
202012 2.190 109.897 2.579
202103 0.610 111.754 0.706
202106 3.650 114.631 4.121
202109 3.420 115.734 3.824
202112 2.350 117.630 2.586
202203 5.030 121.301 5.367
202206 2.410 125.017 2.495
202209 4.910 125.227 5.074
202212 2.670 125.222 2.760
202303 4.860 127.348 4.939
202306 5.240 128.729 5.268
202309 5.380 129.860 5.362
202312 4.360 129.419 4.360

Add all the adjusted EPS together and divide 10 will get our e10.


United Therapeutics  (NAS:UTHR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

United Therapeutics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=233.85/12.96
=18.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of United Therapeutics was 80.06. The lowest was 10.81. And the median was 21.68.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


United Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of United Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069